Alvotech has delivered on recent indications that it would look to use in-licensing deals to supplement its in-house biosimilars pipeline, striking a licensing deal with BiosanaPharma that will see the two companies collaborate on co-developing a rival to Novartis/Genentech’s Xolair (omalizumab) asthma and spontaneous urticaria treatment.
Alvotech In-Licenses Xolair Rival From BiosanaPharma
Co-Development Deal Will See Pair Collaborate On Omalizumab Biosimilar
Alvotech has delivered on indications that it would look to collaborate on certain biosimilar opportunities in future, striking a licensing deal with BiosanaPharma that will see the two firms partner to co-develop an omalizumab biosimilar rival to Xolair.
